20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19+0.00 (+1.30%)
Close on Nov 17, 2026Market cap $2.39MP/E –Yield –
20/20 Biolabs r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $592.57K, down 53.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $592.57K | -53.0% |
| FY2024 | Dec 31, 2024 | $1.26M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $257.63K | – |
| Q1 FY2026 | Mar 31, 2026 | $153.48K | – |
| Q2 FY2025 | Jun 30, 2025 | $194.12K | – |
| Q1 FY2025 | Mar 31, 2025 | $136.83K | – |
See a number that looks wrong?